Logo image of AGL

AGILON HEALTH INC (AGL) Stock Fundamental Analysis

NYSE:AGL - New York Stock Exchange, Inc. - US00857U1079 - Common Stock - Currency: USD

2.48  +0.14 (+5.98%)

After market: 2.49 +0.01 (+0.4%)

Fundamental Rating

3

Overall AGL gets a fundamental rating of 3 out of 10. We evaluated AGL against 102 industry peers in the Health Care Providers & Services industry. The financial health of AGL is average, but there are quite some concerns on its profitability. While showing a medium growth rate, AGL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AGL had negative earnings in the past year.
In the past year AGL has reported a negative cash flow from operations.
In the past 5 years AGL always reported negative net income.
In the past 5 years AGL always reported negative operating cash flow.
AGL Yearly Net Income VS EBIT VS OCF VS FCFAGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

AGL has a Return On Assets of -12.52%. This is in the lower half of the industry: AGL underperforms 79.41% of its industry peers.
The Return On Equity of AGL (-48.37%) is worse than 70.59% of its industry peers.
Industry RankSector Rank
ROA -12.52%
ROE -48.37%
ROIC N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
AGL Yearly ROA, ROE, ROICAGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

AGL has a Gross Margin of 3.15%. This is amonst the worse of the industry: AGL underperforms 83.33% of its industry peers.
AGL's Gross Margin has declined in the last couple of years.
AGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
AGL Yearly Profit, Operating, Gross MarginsAGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

5

2. Health

2.1 Basic Checks

AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGL has been increased compared to 1 year ago.
AGL has more shares outstanding than it did 5 years ago.
AGL has a better debt/assets ratio than last year.
AGL Yearly Shares OutstandingAGL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AGL Yearly Total Debt VS Total AssetsAGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

AGL has an Altman-Z score of 2.04. This is not the best score and indicates that AGL is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of AGL (2.04) is comparable to the rest of the industry.
AGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.04
ROIC/WACCN/A
WACC9.13%
AGL Yearly LT Debt VS Equity VS FCFAGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

AGL has a Current Ratio of 1.20. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
AGL's Current ratio of 1.20 is on the low side compared to the rest of the industry. AGL is outperformed by 64.71% of its industry peers.
A Quick Ratio of 1.20 indicates that AGL should not have too much problems paying its short term obligations.
The Quick ratio of AGL (1.20) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.2
Quick Ratio 1.2
AGL Yearly Current Assets VS Current LiabilitesAGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for AGL have decreased by -9.26% in the last year.
Looking at the last year, AGL shows a very strong growth in Revenue. The Revenue has grown by 25.17%.
AGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.14% yearly.
EPS 1Y (TTM)-9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
Revenue 1Y (TTM)25.17%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%-4.46%

3.2 Future

The Earnings Per Share is expected to grow by 26.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.65% on average over the next years. This is quite good.
EPS Next Y46.77%
EPS Next 2Y26.54%
EPS Next 3Y21.65%
EPS Next 5Y26.11%
Revenue Next Year-1.78%
Revenue Next 2Y3.89%
Revenue Next 3Y8.83%
Revenue Next 5Y10.66%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AGL Yearly Revenue VS EstimatesAGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
AGL Yearly EPS VS EstimatesAGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGL Price Earnings VS Forward Price EarningsAGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGL Per share dataAGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as AGL's earnings are expected to grow with 21.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.54%
EPS Next 3Y21.65%

More info and screens

0

5. Dividend

5.1 Amount

AGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGILON HEALTH INC

NYSE:AGL (5/20/2025, 8:04:00 PM)

After market: 2.49 +0.01 (+0.4%)

2.48

+0.14 (+5.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners77.43%
Inst Owner Change-3.72%
Ins Owners1.81%
Ins Owner Change19.47%
Market Cap1.02B
Analysts66.4
Price Target4.4 (77.42%)
Short Float %7.23%
Short Ratio3.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)204.94%
Min EPS beat(2)-12.63%
Max EPS beat(2)422.51%
EPS beat(4)2
Avg EPS beat(4)63.23%
Min EPS beat(4)-171.08%
Max EPS beat(4)422.51%
EPS beat(8)3
Avg EPS beat(8)17.69%
EPS beat(12)4
Avg EPS beat(12)-4.32%
EPS beat(16)5
Avg EPS beat(16)-93.26%
Revenue beat(2)1
Avg Revenue beat(2)0.18%
Min Revenue beat(2)-0.56%
Max Revenue beat(2)0.91%
Revenue beat(4)1
Avg Revenue beat(4)-1.95%
Min Revenue beat(4)-5.86%
Max Revenue beat(4)0.91%
Revenue beat(8)4
Avg Revenue beat(8)0.27%
Revenue beat(12)8
Avg Revenue beat(12)1.41%
Revenue beat(16)12
Avg Revenue beat(16)1.5%
PT rev (1m)26.77%
PT rev (3m)49.7%
EPS NQ rev (1m)-58.51%
EPS NQ rev (3m)-51.91%
EPS NY rev (1m)5.65%
EPS NY rev (3m)16.91%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)-8.49%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)-9.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.17
P/FCF N/A
P/OCF N/A
P/B 2.05
P/tB 2.51
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS14.5
BVpS1.21
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.52%
ROE -48.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.15%
FCFM N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
F-Score4
Asset Turnover3.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 147.45%
Cap/Sales 0.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.2
Quick Ratio 1.2
Altman-Z 2.04
F-Score4
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)186.26%
Cap/Depr(5y)133.4%
Cap/Sales(3y)0.87%
Cap/Sales(5y)0.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
EPS Next Y46.77%
EPS Next 2Y26.54%
EPS Next 3Y21.65%
EPS Next 5Y26.11%
Revenue 1Y (TTM)25.17%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%-4.46%
Revenue Next Year-1.78%
Revenue Next 2Y3.89%
Revenue Next 3Y8.83%
Revenue Next 5Y10.66%
EBIT growth 1Y-23.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.55%
EBIT Next 3Y28.85%
EBIT Next 5Y19.01%
FCF growth 1Y60.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.07%
OCF growth 3YN/A
OCF growth 5YN/A